Status:
COMPLETED
The Effect of Sodium on Erythrocyte Salt Sensitivity, Syndecan-1 and Heparin Sulfate in Healthy Subjects.
Lead Sponsor:
Frank Mose
Collaborating Sponsors:
Region MidtJylland Denmark
Conditions:
Sodium
Renal Function
Eligibility:
All Genders
18-50 years
Phase:
NA
Brief Summary
The study was a double-blinded, randomized, placebo-controlled cross-over study. 27 healthy subjects received a four days standardized, sodium reduced diet (100 mmol sodium) and treatment with sodium ...
Detailed Description
Background: The endothelium is lined with endothelial glycocalyx (EG). EG protects the endothelium and functions as a barrier between blood and endothelium. Due to negative charges EG has a strong abi...
Eligibility Criteria
Inclusion
- Both gender
- Age 18-50 years,
- BMI 18.5-30.0 kg/m2,
- Signed concent.
- Fertile women with safe contraception during the whole examination period.
Exclusion
- Alcohol consumption \> 7 drinks per week for women and, \> 14 drinks per week for men.
- Smoking,
- Substance abuse
- Current use of medicine except contraception,
- Office BP \> 140/90
- History or signs of clinically relevant kidney, heart, liver, lung, neurological, or endocrine diseases, neoplastic disorders,
- Pregnancy or lactation
- Blood donation within 1 month of the first investigation,
- Clinically relevant abnormal blood/urine sample or electrocardiography.
- Withdrawal criteria:
- Development of exclusion criteria
- Suspicion of poor compliance to study medication
- Withdrawal of signed concent.
Key Trial Info
Start Date :
May 18 2016
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 13 2017
Estimated Enrollment :
27 Patients enrolled
Trial Details
Trial ID
NCT06968182
Start Date
May 18 2016
End Date
January 13 2017
Last Update
May 25 2025
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.